3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other solid neoplasm
1
Genitourinary
1
CNS
1
Conditions
Multiple Myeloma
5
Brain Neoplasms
3
Osteosarcoma
2
Neuroectodermal Tumors, Primitive
2
Neoplasms
2
Melanoma
2
Medulloblastoma
2
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Glioma
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma, Kaposi
1
Sarcoma, Ewing
1
Sarcoma
1
Salivary Gland Neoplasms
1
Rhabdomyosarcoma
1
Retinoblastoma
1
Rectal Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pinealoma
1
Pancreatic Neoplasms
1
Oligodendroglioma
1
Interventions
Melphalan
4
Irinotecan
4
Filgrastim
4
Cyclophosphamide
4
Busulfan
4
fludarabine
3
Topotecan
3
Temozolomide
3
Granulocyte Colony-Stimulating Factor
3
pegfilgrastim
2
liposomal doxorubicin
2
Thiotepa
2
Sirolimus
2
Peripheral Blood Stem Cell Transplantation
2
Doxorubicin
2
Bone Marrow Transplantation
2
trioctyl phosphine oxide
1
ribociclib
1
regorafenib
1
poly ICLC
1
pembrolizumab
1
pegylated granulocyte colony-stimulating factor
1
omburtamab I-131
1
olaparib
1
mocetinostat
1
lexatumumab
1
irinotecan sucrosofate
1
fludarabine phosphate
1
cixutumumab
1
ceritinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Rhabdomyosarcoma
×
Thalidomide
×
Clear all
NCT01661400
2024-01-31
ASCR
Washington University School of Medicine
Phase 1
Completed
14 enrolled